143
Participants
Start Date
April 11, 2014
Primary Completion Date
July 17, 2018
Study Completion Date
July 17, 2018
Eculizumab
Induction Phase: 900 mg IV weekly for 4 weeks, followed by 1200 mg for the fifth dose; Maintenance Phase: 1200 mg IV every 2 weeks
Placebo
Induction Phase: matching placebo (900 mg) IV weekly for 4 weeks, followed by matching placebo (1200 mg) for the fifth dose; Maintenance Phase: matching placebo (1200 mg) IV every 2 weeks
Cheng Hsin General Hospital, Taipei
Hospital General de Agudos Juan Antonio Fernandez, Ciudad Autonoma, Buenos Aires
University of Sydney, Brain and Mind Center, Camperdown
St. Vincent's Hospital Melbourne, Fitzroy
Århus Universitetshospital, Aarhus
Clinical Hospital Centre Zagreb, Zagreb
Multiple Sclerosis Comprehensive Care Center, NYU Langone Medical Center, New York
Navamindradhiraj University, Vajira Hospital, Dusit
National Cancer Center, Goyang-si
Thammasat University Hospital, Pathum Thani
Hospital Universitario Reina Sofia, Córdoba
University of Pittsburgh, Pittsburgh
Universitaetsmedizin Rostock, Klinik für Neurologie, Rostock
Hospital of the University of Pennsylvania, Philadelphia
Georgetown University Hospital, Washington D.C.
University of Maryland Medical Center, Baltimore
John Hopkins University School of Medicine, Baltimore
Hospital Universitario Clinico San Carlos, Madrid
Neurological Services of Orlando, Orlando
University of Miami McKnight Brain Institute, Miami
Sunprasitthiprasong Hospital, Ubon Ratchathani
Istanbul University Cerrahpasa Medical Faculty, Istanbul
Istanbul Bilim Universty Medical Fac., Istanbul
Dokuz Eylul University Medicine Faculty, Izmir
Baptist Health Lexington, Lexington
Kocaeli University Medical Faculty, Kocaeli
The Ohio State University, Wexner Medical Center, CarePoint at Gahanna, Gahanna
Fort Wayne Neurological Center, Fort Wayne
Hospital de Cruces, Barakaldo
Hospital Kuala Lumpur, Kuala Lumpur
Ondokuz Mayis Univ. Med. Fac., Samsun
Mayo Clinic - Rochester, Rochester
Washington University School of Medicine, St Louis
University of Kansas Medical Center, Kansas City
Universitaetsklinikum Heidelberg, Abteilung Neuroonkologie, Heidelberg
Multiple Sclerosis Treatment Center of Dallas, Dallas
Azienda Ospedaliera Universitaria Federico II, Napoli
Klinikum rechts der Isar der TU Muenchen, Neurologische Klinik und Poliklinik, Munich
University of Utah Health Care, Salt Lake City
Mayo Clinic Arizona, Scottsdale
The Research Center of Southern California, Carlsbad
Universitaria Policlinico di Catania, Catania
Swedish Neuroscience Institute, Seattle
First Pavlov State Medical University of St.Petersburg, Saint Petersburg
"SBEIHPE Rostov SMU of MoH of RF", Rostov-on-Don
Republican Clinical Hospital for Rehabilitation of Healthcare Ministry of Republic of Tatarstan, Kazan'
FSBHI 'Siberian Clinical Center of FMBA', Krasnoyarsk
Federal State Budget Institution of Healthcare - Siberian District Medical Center of FMBA of Russia, Novosibirsk
Hospital J. M. Ramos Mejia, Ciudad Autonoma, Buenos Aires
Hospital Universitario Austral, Pilar
Fundacion Rosarina de Neuro Rehabilitacion, Rosario
Vseobecna fakultni nemocnice Neurologicka klinika, Prague
Prince of Wales Hospital, Shatin
Azienda Ospedaliera San Camillo Forlanini, Rome
Neurological Centre of Latium Dipartimento di Neuroscienze, Rome
Chiba University Hospital, Chiba
Hyogo College of Medicine Hospital, Nishinomiya-shi
Kyoto Min-iren Chuo Hospital, Kyoto
Tohoku University Hospital, Sendai
Tokyo Medical and Dental University, Bunkyo-ku
Yamaguchi University Hospital, Ube-shi
Kyushu University Hospital, Fukuoka
National Center Hospital, NCNP, Tokyo
Korea University Anam Hospital, Seoul
Seoul University National Hospital, Seoul
Severance Hospital, Yonsei University, Seoul
Samsung Medical Center, Seoul
Hacettepe University Medical Faculty, Ankara
The Walton Centre, Liverpool
John Radcliffe Hospital, Oxford
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY